Clinical Trial

A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and PK/PD profiles of RG002C0106 injection in healthy adult subjects. The study will be divided into the following parts: Part A, conducted : SAD stage Part B, conducted: MAD stage
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-02; most recent amendment 2026-03-01.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-03-01
Trial Details
NCT Number NCT06494527
Lead Sponsor Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
Conditions Safety Issues
Enrollment 30 participants
Start Date 2024-10-18
Primary Completion 2026-08-20 (estimated)
Study Completion 2026-08-20 (estimated)
Updated on ClinicalTrials.gov 2026-03-03